3C Therapeutics Develops Modular Platform for Degrader-Antibody Conjugate Creation

3C Therapeutics is developing a modular platform designed to facilitate the creation of degrader-antibody conjugates (DACs). The company intends to provide a standardized backbone that allows pharmaceutical partners to attach a variety of therapeutic targets to their delivery system, aiming to streamline the development process for these complex molecules.

The company’s approach focuses on creating a “plug and play” architecture that supports a broad range of target applications. By offering a universal framework, 3C Therapeutics seeks to address the technical challenges associated with linking protein degraders to antibodies. This strategy positions the firm to support external partners in the growing field of DAC research, where the combination of targeted antibody delivery and intracellular protein degradation remains a primary area of investigation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: May 13, 2026

Author

GOAI